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The case for cancer prevention in Europe is the same as for all other parts
of the world. The number of cancers is increasing, driven by demographic
change and evolution in the exposure to risk factors, while the cost of
treating patients is likewise spiralling. Estimations suggest that around
40% of cancers in Europe could be prevented if current understanding of
risk and protective factors was translated into effective primary prevention,
with further reductions in cancer incidence and mortality by screening,
other approaches to early detection, and potentially medical prevention.
However, the infrastructure for cancer prevention tends to be fragmented
between and within different countries in Europe. This lack of a coordi-
nated approach recently led to the foundation of Cancer Prevention Eur-
ope (Forman et al., 2018), a collaborative network with the main aims of
strengthening cancer prevention in Europe by increasing awareness of the
needs, the associated required resources and reducing inequalities in access
to cancer prevention across Europe. This article showcases the need for
strengthening cancer prevention and introduces the objectives of Cancer
Prevention Europe and its foreseen future role in reducing the European
cancer burden.
1. The case for prevention
The case for cancer prevention in Europe, at a funda-
mental level, is the same as for all other parts of the
world. The number of cancers is increasing, driven by
demographic change and evolution in the exposure to
risk factors, while the cost of treating patients is like-
wise spiralling. The most recent report on 25 cancers
in the 40 countries of Europe estimated 3.91 million
new cases (excluding nonmelanoma skin cancer) and
1.93 million deaths in 2018 (Ferlay et al., 2018). This
corresponds to an age-standardized cancer incidence
rate of 374 cases per 100 000 population (European
age standard), with some variation across the countries
(Fig. 1). In the European Union (EU)-28, the estimated
number of new cases of cancer was ~ 1.6 million in
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males and 1.4 million in females, with 790 000 men and
620 000 women dying from the disease. The number of
cancers on the continent is projected to increase to
4.75 million cases and 2.55 million deaths in 2040 primar-
ily as a result of population ageing and growth (GCO
2018). This represents an overall increase in mortality of
32%, that is an additional 620 000 people dying each year.
In Europe, other noncommunicable diseases (NCDs),
including cardiovascular disease, diabetes and chronic
respiratory illnesses, also place a heavy burden on health
systems, but here progress in treating or controlling the
diseases in their early phases has been more effective.
The complexity and diversity of cancer, occurring as it
does in different organs and cell types with associated
intratumour heterogeneity, implies the need for a multi-
tude of tests for early detection coupled with treatments
tailored to specific types of cancers. This is quite differ-
ent in scope to other NCDs where, for example, pro-
gress has been made in controlling blood pressure or
cholesterol through the development of widely applica-
ble drugs, such as antihypertensives and statins. The
result is that cancer is now the leading cause of prema-
ture death (defined as death below the age of 70 years)
in 28 of the 40 countries of Europe and is the second
most common in the remaining countries (Ferlay et al.,
2018). Furthermore, while there is good news in terms
of improvement in cancer survival in Europe, cancer
survivorship also entails long-term follow-up and care
with the attendant demands on health services (Allemani
et al., 2018).
In contrast to the dominance of cancer in terms of
disease burden in Europe and the high proportion of
cancers attributable to modifiable factors, the majority
of cancer research investment continues to be made in
basic science and clinical translational research with
the focus on the development of new therapies or
improving treatment. In addition, investment in pri-
mary prevention has often been neglected partly
because the results are difficult to recognize in individ-
uals and its impact may take several decades to
emerge. For example, in data provided by the Interna-
tional Cancer Research Partnership for the United
Kingdom (UK), France and the Netherlands (for 2014
and 2015, the last years with complete data), 57% of
funding from government and nongovernment organi-
zation sectors was assigned to therapy-oriented biology
and drug development with 7% to prevention and
13% each to aetiology and to early detection, diagno-
sis and prognosis (ICRP 2018). Private sector funding
of cancer research has little incentive to invest in pre-
vention, besides research related to vaccine and early
detection technology development, and thus, the balance
is further skewed if an analysis of all funding sources is
conducted. Exciting developments in precision oncology
Fig. 1. Age-standardized cancer incidence rate in European countries (both sexes combined, excluding nonmelanoma skin cancer, using
World Standard Population).
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drugs and immunotherapy promise a step-change improve-
ment in cancer survival, but come at high cost and by defi-
nition benefit a few subsets of patients.
It is not alarmist to conclude that the status quo in
relation to cancer control measures threatens the sus-
tainability of healthcare provision in Europe. The eco-
nomics of a primary focus on cancer treatment do not
make for cost-effective cancer control policies unless
aligned to public health strategies for prevention.
There are evidence-based and cost-effective preven-
tive interventions available for cancer, based on prior
research into aetiology. In addition, primary preven-
tion offers the most advantageous approach to reduc-
ing cancer and other NCDs by reducing common risk
factors and therefore producing important co-benefits
for health (Espina et al., 2013). Primary prevention
coupled with secondary prevention through early
detection of premalignancy can avoid not only medical
costs, but also the considerable physical, social and
psychological comorbidities and suffering associated
with most cancer treatments. Tertiary prevention of
cancer recurrence among survivors adds further weight
to a balanced approach to prevention and treatment.
Indeed from a health, social and economic viewpoint,
a more systematic and structured approach to cancer
prevention in Europe is a logical necessity.
Any strategic approach to cancer prevention in Eur-
ope needs to recognize heterogeneity across the conti-
nent, both in the pattern of cancers and the stage of
implementation of the available preventive interven-
tions. In Bulgaria, Romania and some Baltic States,
for example, the prevalence of persistent human papil-
lomavirus (HPV) infection is rising in the absence of
HPV vaccination, and as a consequence of this and of
the lack of effective screening, cervical cancer incidence
rates are on the increase (Arbyn et al., 2017). In
France, the HPV vaccination rate among young girls is
only around 25%. Europe has the highest smoking
rates of any World Health Organization (WHO) region,
but this masks considerable differences (EURO 2017).
While countries like Sweden, Iceland, Ireland, Norway
and the UK have achieved significant reductions in
smoking in recent years, other countries like Hungary
and Cyprus have seen little change. Alcohol consump-
tion is the second most common cause of cancer in
France (Shield et al., 2017), after smoking, with this
risk factor having been under-emphasized as a priority
for cancer prevention, as has avoidance of excess expo-
sure to sunlight. The most recent report on implementa-
tion of cancer screening programmes for cervix, breast
and colorectal cancers shows a general improvement in
the EU, but nevertheless reveals marked differences
among countries (Ponti et al., 2017).
Recent detailed estimates in France, the UK and
Germany suggest that around 40% of cancers in Eur-
ope could be prevented if current understanding of
established risk and protective factors was translated
into effective primary prevention (Behrens et al., 2018;
Brown et al., 2018; Gredner et al., 2018; Mons et al.,
2018; Soerjomataram et al., 2018). Cancer screening
and other approaches to early detection of premalig-
nant lesions or surveillance among very high-risk
groups can also contribute to reduce cancer incidence
and mortality. Interventions such as physical activity
among breast cancer survivors offer exciting opportu-
nities to improve prognosis and quality of life among
cancer survivors (Friedenreich et al., 2017). In due
course, additional benefits may come from medical
prevention among cancer survivors or through surveil-
lance of high-risk individuals or groups in the general
population (Cuzick, 2017).
Successful cancer prevention is not a trivial chal-
lenge. It requires considerable commitment to imple-
mentation at national level through strategies that
reach all segments of society. Solutions cannot be
aimed only at individuals (as characterized by the
European Code against Cancer (Schuz et al., 2015))
but must be supported by legislative and regulatory
measures. Some exposures, notably reduction in expo-
sure to air pollution, require international agreements
in order to be truly effective. A cautionary note is
merited in some areas of prevention where ‘more is
less’, either because approaches being implemented are
not evidence-based or because the magnitude of any
effect would be insignificant. An example is the over-
diagnosis and over-treatment of some cancers, for
example, small papillary thyroid cancers (Vaccarella
et al., 2016).
Notwithstanding the challenges in implementing pre-
ventive interventions, the prize is of great value and
complementary to that of treating and caring for can-
cer patients more effectively. Reducing the number of
patients developing cancer should result in greater
resources being available to treat those patients with
the most effective therapies available.
2. The need for strengthening cancer
prevention in Europe
Cancer prevention has a broad scope. As mentioned
above, the field encapsulates surveillance and descrip-
tive data (e.g. incidence, mortality, survival and preva-
lence; economic analyses including cost-effectiveness;
prevalence of exposure to risk factors) as well as the
areas of primary, secondary and tertiary prevention.
Prevention may be aimed at the whole population, for
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example as with antismoking legislation, or at specific
high-risk subgroups, for example, surveillance colono-
scopy in patients previously diagnosed with polyps,
with aspirin being under consideration for different at-
risk groups.
The broad scope of prevention is naturally matched
by a broad scope of practitioners. Indeed, the full
range of prevention activities relies on an interdisci-
plinary approach that encompasses epidemiology, can-
cer registries, basic and applied laboratory sciences,
public health, general practice, clinical science, health
services, health psychology, the social sciences and
implementation science among other disciplines. The
contribution of social sciences, humanities and
anthropology is particularly needed. It is now per-
ceived that the traditional health promotion/health
education paradigm based on individual advice (e.g.
from physicians or nurses), though laudable, is not
sufficient and tends to create social disparities in
terms of efficacy. Social sciences, and particularly
anthropology, help to embed behavioural changes in
cultural contexts. This is particularly true, for exam-
ple, of obesity, which is not equally perceived in all
social strata and cultural subgroups. Indeed, all can-
cer control initiatives should undergo a thorough and
ongoing evaluation as to whether they diminish or
exacerbate social inequalities within and between
countries (Vaccarella et al., 2018).
The broad scope of disciplines brings with it a broad
scope of institutions and professional organizations.
Perhaps partially as a result of this situation, at insti-
tutional or even national level the infrastructure for
cancer prevention tends to be fragmented. There are
few exemplars of ‘prevention centres’ analogous to pri-
mary, secondary or tertiary care centres. Likewise,
there are few centres of research excellence in preven-
tion, unlike the many world class cancer treatment
centres in Europe. International collaborative consor-
tia (e.g. the European Organisation for Research and
Treatment of Cancer) are the norm in the employment
of clinical trials in development of new treatments,
whereas the absence of analogous structures is one fac-
tor which inhibits the development of world class pre-
vention research.
Most often there is a separation between centres of
expertise in cancer prevention and in cancer treatment,
reflected in differences in organizational responsibility,
perception and culture. Health care is usually the polit-
ical responsibility of Government (Ministry of Health
or equivalent, and their respective health authorities),
performed by healthcare professionals and undertaken
in hospitals and primary care centres. These parame-
ters of responsibility, expertise and location are
considerably more complicated for prevention. Many
of the above-mentioned disciplines required for cancer
prevention are to be found, for example, in institutes
of public health, universities, charities, and health and
non-health-related government departments or cancer
centres. Linkages in the context of cross-sectorial ini-
tiatives or strategies such as ‘Health in All Policies’
would make good sense in cancer prevention (Espina
et al., 2013).
Successful coordination of cancer prevention in Eur-
ope requires long-term vision, a dedicated research
agenda, and strategically targeted funding. It also
requires a sustainable infrastructure and cooperation
between countries and programmes to fill gaps in the
evidence base for prevention, to avoid common pitfalls
in implementation and to share capacity for research
training and quality improvement. Comprehensive
Cancer Centres are in an excellent position to offer a
pan-European cancer research infrastructure, linking
treatment and prevention with research and education,
and thus connecting research with the healthcare sys-
tems (Celis and Pavalkis, 2017). For all these reasons,
the initiative was taken within the FP7 Eurocan Plat-
form project to create a network for strengthening
cancer prevention in Europe, called ‘Cancer Prevention
Europe’. Close collaboration between Cancer Core
Europe and Cancer Prevention Europe, involving
other organizations and stakeholders active in cancer
prevention and treatment, will ensure that develop-
ments in understanding the causes of cancer will trans-
late both into clinical and population-based
innovations and practices, addressing the whole cancer
continuum in partnership.
3. The objectives of Cancer Prevention
Europe
Cancer Prevention Europe originated in a general and
collective recognition that cancer prevention in Europe
is fragmented and lacks an overall strategy. In addi-
tion, the requirement for a more integrated approach
in conjunction with related innovations in the area of
cancer treatment was clear: the formation of Cancer
Core Europe (Celis and Pavalkis, 2017) offered an
opportunity in this respect.
Cancer Prevention Europe was created, therefore,
initially as a consortium of a number of leading Euro-
pean research institutions (Cancer Research UK, London,
UK; Danish Cancer Society, Copenhagen, Denmark;
European Institute of Oncology, Milan, Italy; German
Cancer Research Centre, Heidelberg, Germany; Imperial
College London, London, UK; Karolinska Institute,
Stockholm, Sweden; UK Therapeutic Cancer Prevention
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Network, Leicester, UK; World Cancer Research Fund
International, London, UK/Wereld Kanker Onderzoek
Fonds, Amsterdam, the Netherlands) committed to priori-
tizing cancer prevention. Each consortium member made
a financial contribution to fund a small secretariat at
IARC and to initiate specific strategic areas of collabora-
tive research. A full description of the manifesto of the
consortium has recently been published (Forman et al.,
2018).
In brief, a number of objectives have emerged from
this first phase in the development of the Cancer
Prevention Europe initiative:
 To provide an infrastructure for coordinated
cancer prevention research at the European level
which is sustainable and open to expansion with
new members over time;
 To communicate and disseminate to policymak-
ers the opportunities and benefits of available
preventive interventions;
 To formulate the scope of prevention research and
to advocate for increased investment in this area;
 To drive innovative interdisciplinary research,
including the opportunities afforded by advances
in understanding cancer aetiology;
 To bridge the identification of risk factors
through to the development and implementation
of preventive interventions;
 To enable the translation of research on preven-
tive interventions into effective cancer policy;
 To provide a platform for advocacy for cancer
prevention among a wide set of stakeholder
engagement, including citizens and patients.
The development of an alliance of organizations
focused on cancer prevention also promises to provide
a focal point for development of professional training
and career development in an area where no simple
career pathway is evident. This initiative should con-
sider the provision of dedicated academic courses and
qualifications in the area of cancer prevention, with
teaching provided from among the different disciplines
implicated.
There are a number of challenges facing Cancer
Prevention Europe. First, the consortium needs to iden-
tify a mechanism within the European funding tools to
obtain the required financing to fulfil its objectives. One
option is the new ‘mission-orientated’ research agenda,
but this is not the only mechanism that can be envis-
aged. For now, the commitment is high among the foun-
der members of the consortium, but accessible resources
remain limited. Second, Cancer Prevention Europe needs
to encompass innovative research and collaboration
across the whole of Europe, including the specific
challenges of inequalities both between and within coun-
tries. The consortium is thus seeking mechanisms to
broaden participation and achieve this critical mass with-
out diluting commitment and quality. Third, Cancer
Prevention Europe recognizes the importance of an inte-
grated approach that encompasses prevention and treat-
ment in cancer research and cancer control: this requires
a European-level vision that carries all of these areas for-
ward to deliver sustainable cancer services.
4. The next steps for Cancer
Prevention Europe
The ambition of Cancer Prevention Europe is to trans-
form the current research landscape through this new
interdisciplinary consortium of institutes and organiza-
tions. The consortium aims to conduct innovative
world class research capable of translation into effec-
tive cancer prevention guidelines and policies at
national and international level. Cancer Prevention
Europe offers an integrated infrastructure capable of
delivering such high-quality research in a collaborative,
interdisciplinary manner.
The innovative science behind cancer prevention
offers an opportunity to add value to a number of
prior investments at the level of the European Com-
mission, including large collaborative research studies,
for example on the exposome (e.g. Exposomics, HELIX)
and research infrastructure investments, including bio-
banks (Biobanking and BioMolecular resources Research
and Infrastructure – European Research Infrastructure
Consortium) and large population-based cohort studies
of chronic diseases (e.g. Biobanking and BioMolecular
resources Research and Infrastructure – Large Prospec-
tive Cohorts), which all provide platforms for research
on cancer prevention.
Inherent to the philosophy of Cancer Prevention
Europe is the sharing of resources (including existing
research platforms, biospecimen repositories and
cohorts); the sharing of data (enabling multicentre,
trans-national research projects); and the sharing of
information (through the creation of a central reposi-
tory of information pertinent to cancer prevention).
Suitable and acceptable legal frameworks would be
established within Cancer Prevention Europe to permit
information exchange, to monitor regulations and to
highlight potential and actual barriers to progress
through implemented legislation.
The new mission-oriented approach to European
research investment provides one major opportunity to
enhance cancer prevention and better align the invest-
ments in research with the needs of Member States in
relation to cancer control, thus optimizing benefits for
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all European citizens. This approach aligns well with the
recent WHO European Health Report 2018 (EURO
2018) and the World Health Assembly 2017 resolution
on cancer prevention and control (WHO 2017).
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